ALK and neoplasm: DNAfusion can characterize the gene fusion by identifying the breakpoint position and the DNA sequences around the breakpoint in both EML4 and ALK. Furthermore, DNAfusion determines the read depth at the breakpoint in EML4. This serves as a surrogate for the ctDNA load in the blood sample, which in turn reflects the tumor burden [23–25].